✦ LIBER ✦

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

✍ Scribed by Antonio M. P. Omuro; Mark G. Kris; Vincent A. Miller; Enrico Franceschi; Neelam Shah; Daniel T. Milton; Lauren E. Abrey

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 97 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Utility of screening procedures for dete

Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma

✍ Edith A. Perez; Charles L. Loprinzi; Jeff A. Sloan; David T. Owens; Paul J. Novo 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 3 views

## Background: Studies evaluating the efficacy of routine follow-up testing in detecting disease recurrence in treated lung carcinoma patients are lacking. ## Methods: To investigate this subject, the authors studied 115 patients who had previously been entered on north central cancer treatment g

Emergence of increased cerebral metastas

Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma

✍ Amy Law; Daniel D. Karp; Thomas Dipetrillo; Benedict T. Daly 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

High dose tamoxifen plus cisplatin and e

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

✍ Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh; Chong-Jen Yu; Jing-Fang Lin; Pan-Ch 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## BACKGROUND. Tamoxifen sensitizes cancer cells to chemotherapeutic agents. High dose tamoxifen has been tested in the treatment of patients with melanoma and other cancers. The authors conducted a Phase II study of high dose tamoxifen plus cisplatin and etoposide for patients with advanced, inop

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg

Pro-gastrin–releasing peptide as a facto

Pro-gastrin–releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

✍ Kan Yonemori; Minako Sumi; Naoko Fujimoto; Yoshinori Ito; Atsushi Imai; Yoshikaz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

The impact of age on toxicity, response

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

✍ Thomas A. Hensing; Amy H. Peterman; Michael J. Schell; Ji-Hyun Lee; Mark A. Soci 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma wit